Molecular
diagnostics is becoming a dominant platform in clinical medicine and represents
one of the fastest growing segments of the IVD market. As analyst Shara Rosen,
R.T., MBA. details, in recent years years the number of assays introduced has
been growing at a remarkable clip. This report, The World
Market for Molecular Diagnostics (Infectious Disease, Oncology, Blood
Screening, Pre-Natal and Other Areas) represents the fifth time that
Kalorama has conducted a complete study into the market for molecular
diagnostics.
Comprehensive
Coverage of the Molecular Diagnostics Industry
The
report not only contains current market data for business planning, it goes
beyond the numbers to fully assess what is going on in the market and why.
Since the last edition of this report, a lot has changed, and a lot has stayed
the same. There is intense competition but also opportunities for entrants in
some areas.
This
comprehensive seven-country report contains 1,050 pages, 96 tables, and is
designed to help current suppliers and potential market entrants identify and
evaluate major business opportunities emerging in the molecular diagnostics
market during this decade. The report explores business and technological
trends in the US, five major European countries, (France, Germany, Italy,
Spain, UK) and Japan; provides 5- and 10-year test volume/sales forecasts;
estimates shares of leading competitors; compares features of major analyzers;
profiles leading market players; and identifies specific product and business
opportunities facing instrument and consumable suppliers during the next ten
years.
The
molecular
diagnostics market is unquestionably the most rapidly growing segment of
the in vitro diagnostics industry. The next ten years will witness significant
developments in reagent systems and automation, as well as introduction of a
wide range of new products that will require innovative marketing approaches.
The rate of market penetration into routine clinical laboratories, however,
will depend on the introduction of cost-effective and automated systems with
amplification methods.
In
order to successfully capitalize on the opportunities presented by the
molecular diagnostics market, many companies are already exploiting new DNA
probe and biochip technologies as corporate strategic assets, managed in
support of business and marketing strategies. Integrating new technology
planning with business and corporate strategies will be one of the most
challenging tasks for diagnostics companies during the next ten years.
Request a Sample Copy
of World Market for Molecular
Diagnostics, 5th. Edition
Request a Sample Copy
of The 2012 Molecular Diagnostics
Market: DNA Probes and Biochips
More and more laboratories offer complex panels of
tests that help physicians evaluate disease risk and make therapeutic
decisions. Government and private healthcare payers have recognized the value
of new molecular tools and have agreed to pay for them. A desire for better and
faster test results, a preference for tests that are aimed at the patent,
renewed interest in IVD in general and more particularly in molecular IVD has
led to the commercialization of a number of technological tools that make more
sensitive and specific tests possible. Some of these technological innovations
include cost-effective, multiplexed testing platforms coupled with high-powered
software capabilities.
Molecular diagnostics is a complicated market that
requires a thorough analysis to understand. Many reports make bold predictions
which later are proved incorrect by market events. In this report, Kalorama
Information provides revenues and market forecasts, but also looks deeply at
some of the trends in the market and what might impact results in the future.
The report summarizes what is working and what is not working in the past few
years.
-
Sequencing Hype and Reality: Innovations
in DNA Sequencing, Key Players and its Future in Clinical Medicine
-
Pharmacodiagnostics and Where it Stands in 2013
- The Latest Growth Numbers of LDTs,
regulatory activity, and their impact on the Market
-
IVD Directive Update
-
Patent Issues
-
Healthcare Reform, Accountable Care Organizations and Reimbursement
Trends
-
Improvements in Platforms
- Developments in ISH testing, Tissue
Microarrays and Mass Spectroscopy
- Integrated Sample-to-Results Testing
Market size and forecasts in the report are for
manufacturer’s revenues. Secondary and primary resources, including: trade
publications, annual report and interviews with key executives in molecular
diagnostics were used for this study.
